{"id":"placebo-lonafarnib","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL298734","moleculeType":"Small molecule","molecularWeight":"638.83"},"_fixedAt":"2026-03-30T12:27:41.960151","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Farnesyltransferase inhibitors prevent the attachment of farnesyl groups to proteins like RAS and KRAS, which are frequently mutated in cancers and play critical roles in oncogenic signaling. By blocking this modification, lonafarnib disrupts the membrane localization and activation of these proteins, thereby suppressing tumor cell growth and survival pathways.","oneSentence":"Lonafarnib inhibits farnesyltransferase, blocking the post-translational modification of proteins involved in cell proliferation and survival.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:27:47.583Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"KRAS-mutant pancreatic cancer"},{"name":"HRAS-mutant head and neck squamous cell carcinoma"}]},"_fixedFields":["modality→Small Molecule"],"trialDetails":[{"nctId":"NCT03719313","phase":"PHASE3","title":"Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a","status":"COMPLETED","sponsor":"Eiger BioPharmaceuticals","startDate":"2018-12-01","conditions":"Hepatitis Delta Virus","enrollment":407},{"nctId":"NCT02511431","phase":"PHASE2","title":"Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2015-07-29","conditions":"Hepatitis D","enrollment":22},{"nctId":"NCT01495585","phase":"PHASE2","title":"Lonafarnib for Chronic Hepatitis D","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2011-12","conditions":"Hepatitis D","enrollment":14},{"nctId":"NCT00050336","phase":"PHASE3","title":"Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901)(TERMINATED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-12","conditions":"Carcinoma, Non-small-cell Lung, Metastases, Neoplasm","enrollment":702},{"nctId":"NCT00109538","phase":"PHASE3","title":"Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-05","conditions":"Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Myelodysplasia","enrollment":47},{"nctId":"NCT00081510","phase":"PHASE2","title":"Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-12","conditions":"Breast Cancer","enrollment":110}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo Lonafarnib","genericName":"Placebo Lonafarnib","companyName":"Eiger BioPharmaceuticals","companyId":"eiger-biopharmaceuticals","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lonafarnib inhibits farnesyltransferase, blocking the post-translational modification of proteins involved in cell proliferation and survival. Used for KRAS-mutant pancreatic cancer, HRAS-mutant head and neck squamous cell carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}